The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the common ingredient phenylephrine off ...
The agency said an extensive review of available data determined that the ingredient, oral phenylephrine, doesn’t actually ...
A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.
the companies said that the antibody therapy reduced the size of nasal polyps and nasal congestion with a statistically ...
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind ...
In a long-sought move, the Food and Drug Administration on Thursday formally began the process of abandoning oral doses of a ...